Compound for inhibiting HIV infectivity

US6365625B1 · kind B1 · utility

Assignee

• Procept Corporation · US

Inventors

• Shyam K. Singh · Arlington, US
• Raymond J. Patch · Yardley, US
• Peter V. Pallai · Westwood, US
• Edith A. Neidhardt · Boxford, US
• Gerard Palace · Waltham, US
• Kevin J. Willis · Newton, US
• Theresa M. Sampo · Watertown, US
• Kevin McDonald · Merrimack, US
• Zhan Shi · Concord, US

Key dates

• Filing date: Sep 17, 1999
• Grant date: Apr 2, 2002
• Expiry date: Sep 17, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.